Differential Effects of High and Low Frequency Subthalamic Nucleus Deep Brain Stimulation on Force Steadiness in Patients with Parkinson’s Disease: An Exploratory Study Authors: Amin Olamazadeh, Steffen Brenner, Daniela Souza de Oliveira, Martin Regensburger, Alessandro Del Vecchio, Thomas M Kinfe Published: 2026 ABSTRACT AbstractIntroductionDeep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy for patients with Parkinson’s disease (PD). However, the frequency-dependent impact on force steadiness remains largely unknown. This explorative study investigated how stimulation frequency and disease severity influence force steadiness during precision pinch.MethodsForce steadiness was assessed during a precision pinch task in patients with Parkinson’s disease implanted with STN DBS. Ten individuals performed a force tracking task at 10% and 20% of maximal voluntary contraction (MVC) under four stimulation conditions: (a) 130 Hz, (b) 50 Hz, (c) STN DBS “OFF”, and (d) 130 Hz. Force steadiness was quantified as the coefficient of variation (CoV) of force.ResultsPatients with Parkinson’s disease with higher scores (UPDRS-III > 25) showed significantly greater force CoV compared with the subgroup with UPDRS-III ≤ 25 at both contraction levels (10% MVC: U = 2, p = 0.038, Cliff’s δ = 0.83; 20% MVC: U = 1, p = 0.019, Cliff’s δ = 0.92). Within the more impaired subgroup (UPDRS-III > 25), Friedman tests revealed significant STN DBS effects at both contraction levels (10% MVC: χ2(3) = 8.00, p = 0.046; 20% MVC: χ2(3) = 8.00, p = 0.046). Post hoc multiple comparisons with Bonferroni correction indicated that 130 Hz stimulation significantly reduced CoV relative to DBS “OFF” (p = 0.044).ConclusionIn this exploratory study no differential effects were observed in less severely affected patients with Parkinson’s disease between high and low frequency stimulation parameters with respect to force steadiness. Tailoring STN DBS protocols according to individual motor performance characteristics may improve motor pinch performance in patients with Parkinson’s disease relevant for daily critical execution. As a result of selection and analysis bias, further randomized controlled studies are warranted assessing additional STN-DBS parameters and targeting different muscles.Keywords: Parkinson, Precision motor performance, Deep brain stimulation, Subthalamic nucleus Key Summary Points Why carry out the study? Force steadiness and motor pinch performance are deteriorated in patients with Parkinson’s disease. This study assessed the impact of subthalamic deep brain stimulation (STN DBS) frequencies on force steadiness in patients with Parkinson’s disease.How does high versus low frequency STN-DBS compared to STN DBS “OFF” affect precision pinch performance in less versus severely affected patients with Parkinson’s disease? What was learned from the study? No differences between high and low frequency STN DBS were found with respect to force steadiness.High frequency STN DBS force steadiness measures may support optimization of STN-DBS parameters for motor performance.Future targeted clinical large-scale trials with homogenous cohorts and analysis of the entire DBS parameter spectrum are needed before considering hand force variability measures as a possible tool for optimization of STN DBS stimulation protocols. Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting millions of people worldwide and characterized by the core symptom of progressive motor impairment. Common motor symptoms include tremor, rigidity, bradykinesia (slowness of movement), and abnormal gait, all of which significantly impair quality of life and can lead to severe disability [1–4]. These extrapyramidal motor signs not only affect gross movements, such as walking and balance, but can also disrupt fine, precision motor control, relevant for tasks involving steady force production. Standard medical treatment typically begins with dopamine replacement therapy, such as levodopa, which can temporarily alleviate several motor symptoms [5, 6]. However, as the disease progresses or in cases where medication is insufficient or produces side effects, invasive treatment options such as deep brain stimulation (DBS) have become essential in managing PD motor symptoms [7]. Deep brain stimulation, first introduced by Benabid et al. in 1987 [8], is now a widely used and clinically approved neurosurgical treatment for otherwise drug-resistant PD. The most common DBS target in patients with Parkinson’s disease is the subthalamic nucleus (STN-DBS), a region within the basal ganglia that becomes disinhibited as a result of dopaminergic depletion [9]. STN-DBS works by modulating abnormal electrical activity and can effectively improve tremor, bradykinesia, and rigidity [7]. Two main types of STN-DBS protocols are frequently studied: high-frequency stimulation (> 100 Hz) and low-frequency stimulation (< 100 Hz) [5, 6, 10, 11]. While high-frequency STN-DBS is most commonly used to suppress motor symptoms, low-frequency stimulation has also shown potential in treating specific issues such as limb bradykinesia [10, 11]. Still, high-frequency STN-DBS is generally more effective, particularly in improving global motor scores when medication is not used [6]. Despite its benefits, low-frequency STN-DBS may fail to adequately suppress Parkinson’s disease-related pathological beta activity and has a more localized effect on the surrounding tissue compared to high-frequency stimulation [12]. STN-DBS outcomes may also depend on precise targeting within the STN, with specific subregions, commonly referred to as “sweet spots,” offering optimized clinical improvements [5, 6, 13]. While numerous studies have explored the overall motor effects of STN-DBS in patients with Parkinson’s disease [2, 5], not many have assessed its impact on fine motor control, particularly force steadiness. Steady force generation is crucial for many daily activities, yet its modulation under different STN-DBS settings remains poorly understood. Experimental as well as clinical data suggest a strong relationship between force steadiness and modulation of motor unit discharge times, which in turn relay on synaptic input, muscle properties and the motor task executed, thus generating intra- and interindividual variabilities. Furthermore, synaptic input, muscle properties, target force during steady contractions, afferent feedback (load compliance), contraction type (dynamic versus isometric), and amplitude of force fluctuations may strongly vary across different life span (age). Deterioration of force steadiness accounts for different neurological disorders such as for patients with Parkinson’s disease. It has been proposed that an increased variance in the common synaptic input to motor neurons evokes an altered control mechanism due to deterioration in sensorimotor integration and conduction delays, thus leading to muscle stability in patients with Parkinson’s disease characterized by postural instability, disease progression, gait freezing, and the risk of falling. To address this, we investigated the effects of different STN DBS stimulation frequencies on force steadiness in individuals with Parkinson’s disease. We recorded force signals during a controlled precision pinch task under three stimulation conditions: high frequency (130 Hz), low frequency (50 Hz), and STN-DBS “OFF”. By analyzing the coefficient of variation (CoV) of force at two submaximal contraction levels (10% and 20% of maximum voluntary contraction, MVC), we aimed to quantify how different STN-DBS frequency waveforms impacts force consistency along with a comparison of patients with Parkinson’s disease with lower motor impairment (UPDRS-III ≤ 25) to those with higher motor impairment (UPDRS-III > 25). Methods Participants The study included ten participants (eight men and two women) with a mean age of 63.36 ± 8.29 years. All participants have been diagnosed with Parkinson’s disease and were experiencing characteristic symptoms. These participants had STN-DBS devices implanted, manufactured by either St. Jude Medical Infinity (Abbott Laboratories, Chicago, IL, USA) or Medtronic (Medtronic Inc., Dublin, Ireland). The stimulation was delivered in bipolar or monopolar configurations, and all participants received adjunctive STN-DBS at 130 Hz to suppress PD symptoms with a stimulation duration for an average of 2.45 ± 0.74 years. Table 1 summarizes participant and implant characteristics, including the Schwab and England Activities of Daily Living (ADL, %) and Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III, points) under 130 Hz STN-DBS ON / medication ON. All analyses in this study were based on force signals obtained from the force dynamometer. The study protocol was approved by an independent internal local ethics committee (IRB No. 19-339-2-B), conducted in accordance with the principles of the latest revision of the Declaration of Helsinki. Written informed consent was obtained from all participants. Table 1Clinical characteristics and deep brain stimulation parameters (STN; subthalamic nucleus) of the study cohort at baseline (STN-DBS ON / medication ON)ParticipantSTN DBS therapy duration (months)STN DBS parametersDisease duration (years)Age/sexHoehn & YahrLevodopa equivalent dose (mg/d)Independence in activities (%)UPDRS- III (points)Recorded MVC (N)P114130 Hz / 60 µs / bipolar / 0.9 mA1049/F3835901568.2P234130 Hz / 60 µs / bipolar / 2.4 mA1970/M31203403238.6P340130 Hz / 60 µs / bipolar / 3.1 mA1769/M4100702888.7P436130 Hz / 60 µs / bipolar / 2.7 mA1160/M21225802350.4P518130 Hz / 60 µs / bipolar / 01.3 mA1162/F2582303049.8P624130 Hz / 60 µs / bipolar / 2.2 mA1761/M3620801960.2P721130 Hz / 60 µs / bipolar / 2.7 mA765/M33851001160.5P840130 Hz / 60 µs / bipolar / 3.4 mA779/M3240703013.9P935130 Hz / 60 µs / bipolar / 3.3 mA2359/M2635503770.7P1039130 Hz / 60 µs / bipolar / 3.4 mA1469/M2320803643.3STN DBS subthalamic deep brain stimulation, M male, F female, UPDRS Unified Parkinson´s Disease Rating Scale, MVC maximal voluntary contraction Clinical characteristics and deep brain stimulation parameters (STN; subthalamic nucleus) of the study cohort at baseline (STN-DBS ON / medication ON) STN DBS subthalamic deep brain stimulation, M male, F female, UPDRS Unified Parkinson´s Disease Rating Scale, MVC maximal voluntary contraction Experimental Protocol We aimed to assess participants’ force steadiness under different STN-DBS conditions while they performed a force tracking task (Fig. 1). The study was conducted in a single session, beginning with a familiarization and warm-up before the recording session. a Experimental setup: a participant with an STN-DBS implant and a schematic of the force tracking task using a precision pinch on a force-sensitive ball while receiving visual feedback on a monitor. b Example of recorded force signal at 10% MVC. The shaded segments indicate the 6-s windows used to compute the CoV of force. c Ramp trajectory: ramp-up, a 15-s steady hold, a ramp-down phase, and a 20-s rest (3-s ramps for 10% MVC, 6-s ramps for 20% MVC) Upon arrival at the laboratory, participants were already receiving chronic high-frequency STN-DBS at 130 Hz with optimized settings and medication ON as part of their standard clinical care. Each participant was asked to indicate which hand was most affected by their symptoms, and this hand was selected for the task. For three participants (P8, P9, and P10), the more affected hand corresponded to the non-dominant hand. Participants were first instructed to press the force ball by pinching it between their thumb and index finger at their self-perceived maximum voluntary contraction (MVC) for 3–5 s. This value was then used as a reference to set the target force levels (10% and 20% of MVC) for the ramp contractions during the warm-up. The contraction levels (10% and 20% MVC) were selected to focus on low-force conditions, where variability in force output is more pronounced and can be more sensitively detected. These levels were chosen to target conditions requiring precise control of force output. In this phase, participants were asked to follow a ramp trajectory displayed on a screen in front of them, with their real-time force signal superimposed. They performed at least two ramps for each force level, repeating trials if necessary until they could approximately match the requested ramp trajectory. In the warm-up and main recording session, the participants were seated comfortably and instructed to place one of their hands on top of a wooden board placed on a desk in front of the patients. The wooden board was used to keep the force dynamometer in a fixed position and support the participant’s arm in a stable position throughout the experiment. After the warm-up and a 5-min rest, we asked the participants to repeat the MVC twice, and the highest value was recorded to define the target force levels (10% and 20% of MVC) for the main recording session. The session consisted of four isometric ramps for each force level under four STN-DBS conditions (130 Hz-A, STN-DBS “OFF”, 50 Hz, 130 Hz-B) and medication ON, in this order. Each ramp included a linear increase in force (3 s for 10%MVC and 6 s for 20% MVC), a 15-s steady phase, and a 20-s rest between each ramp (Fig. 1). As in the warm-up, participants performed the task by pinching the force ball with the thumb and index finger while following the ramp trajectory on the screen. The order of force levels was randomized across conditions; for example, if a participant began one condition with 10% of MVC, the next condition began with 20% of MVC. After each condition, the STN-DBS frequency was adjusted using the respective clinician programming tablet, with a 5-min rest between conditions. STN DBS Frequency Conditions During the session, each participant performed the pinching task under four different STN DBS frequency conditions and medication ON, presented in a fixed order. The medication ON state was defined as optimized medication protocol for each participant. The first condition involved standard high-frequency stimulation at 130 Hz (130-A), bipolar contact configuration, with a pulse width of 60 µs and an amplitude ranging from 0.9 to 3.4 mA (different for each participant). The second condition was the STN-DBS OFF / medication ON condition, in which the STN-DBS device was completely turned off followed by the third condition used low-frequency STN-DBS at 50 Hz (50 Hz) / medication ON, with the same amplitude and intensity settings as in the 130-A condition. The last and fourth condition, 130-B, was identical to 130-A (STN-DBS ON / medication ON) and repeated as the final trial. A 5-min rest period was provided between conditions to allow participants to adapt to the new stimulation frequency before starting the next trial. The UPDRS III cutoff > 25 was determined prior to study onset as part of the initial study design. Force Recordings Force was measured using a force ball dynamometer (COR2, OTBioelettronica, Turin, Italy) held in place by a custom support attached to the wooden board. The force signals were amplified (× 100) and sampled at 2048 Hz using a 16-bit analog-to-digital converter (Quattrocento, OTBioelettronica) and processed in real-time with OTBioLab software (OTBioelettronica). Target forces (10% and 20% MVC) were calculated automatically based on the measured MVC for each participant. The same setup was used across all conditions. Data Analysis The raw signal obtained from the force transducer was converted into newtons (N) using the calibration parameters of the sensor and amplifier. After the raw signal was converted to newtons, the force signals were low-pass filtered using a fourth-order zero-phase Butterworth filter with a cutoff frequency of 20 Hz [14]. To compute the force CoV, from each trial, the steady hold phase—defined as the middle 6-s of the 15-s plateau—was extracted following reported methodology [15], and the CoV was calculated within this window to quantify force steadiness (Fig. 1). Because not all participants completed four ramps in every condition, the CoV analysis was standardized to two ramps per condition, corresponding to the minimum number available across participants and conditions. When more than two ramps were available, the first two completed ramps were included. This ensured the same number of observations per participant and condition and avoided performance-based trial selection. To further examine variability across participants, we stratified them into two groups according to their UPDRS-III scores (≤ 25 vs. > 25). This threshold was used to stratify participants into groups with lower and higher motor impairment and to facilitate comparisons across disease severity levels. Given the exploratory nature and small sample size of this study, this cutoff was not predefined based on clinical criteria and should be interpreted with caution. Statistical Analysis A non-parametric statistical approach was applied to analyze differences in CoV of force across stimulation conditions. This choice was motivated by the low number of participants and the non-normal distribution of CoV values. A within-subject repeated-measures design was used to compare conditions within the same individuals. First, the Friedman test, a non-parametric alternative to repeated-measures ANOVA, was conducted separately at each contraction level (10% and 20% of MVC) to test for overall differences in CoV across STN-DBS conditions (OFF, 130-A, 50 Hz, 130-B) for all participants. If the Friedman test reached significance (significance level was set at α = 0.05), post hoc pairwise comparisons were performed with Bonferroni correction to adjust for multiple testing. Differences between the two subgroups based on disease severity (UPDRS-III ≤ 25 vs. > 25) were assessed using the Mann–Whitney U test. Within each subgroup, a Friedman test was performed, as mentioned above at the group level. Effect sizes were quantified using Kendall’s W for Friedman tests and Cliff’s δ for between-group comparisons. Data are presented as median [interquartile range (IQR)]. All statistical analyses were performed in MATLAB (The MathWorks, Natick, MA, USA). Results Overall force CoV for the groups stratified by disease severity (Fig. 2a). Participants were divided into two groups based on UPDRS-III scores (Fig. 2b): those scoring ≤ 25 were classified as the mild group (P1, P4, P6, P7; n = 4), and those scoring > 25 as the more impaired group (P2, P3, P5, P8, P9, P10; n = 6). Across both contraction levels (10% and 20% of MVC), patients with higher motor impairment (UPDRS-III > 25) consistently exhibited larger median CoV values compared with those with milder symptoms (UPDRS-III ≤ 25). a Relationship between Schwab and England Activities of Daily Living (ADL, %) and Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III, points) for patients with Parkinson’s disease (P1–P10). Each point represents one participant. The red dashed line indicates the threshold at UPDRS-III = 25 used to stratify participants into lower (≤ 25) and higher (> 25) motor impairment subgroups. b Force CoV (%) at 10% MVC (top) and 20% MVC (bottom) for participants stratified by disease severity (UPDRS-III ≤ 25 vs. > 25). Bars represent median values, error bars indicate interquartile range (IQR), and individual data points are shown. *p < 0.05. Force CoV (%) at 10% MVC (c) and 20% MVC (d) across all participants (P1–P10) for each stimulation condition (130-A, OFF, 50 Hz, 130-B). Colored lines represent the mean CoV per participant averaged across the selected ramps. Gray dots represent individual observations, and box plots summarize the distribution across all observations per condition as median and IQR. Force CoV (%) at 10% MVC (e) and 20% MVC (f) across stimulation conditions, stratified by disease severity (UPDRS-III ≤ 25 vs. > 25). Bars represent median values, error bars indicate IQR, and individual data points are shown. *p < 0.05 The recorded MVC across all participants was 54.3 ± 20.2 N (mean ± SD) and summarized in Table 1. Analysis of CoV of force revealed a consistent pattern across both contraction levels examined (10% and 20% MVC) (Fig. 2c, d). In both cases, the STN-DBS OFF condition was associated with higher CoV values compared to all STN-DBS stimulation conditions. At 10% MVC, the median CoV of force [IQR] was 4.49% [1.84–14.68] for STN-DBS OFF, 2.87% [1.92–8.77] for 130-A, 4.06% [1.77–7.54] for 50 Hz, and 2.63% [1.60–6.30] for 130-B (Fig. 2c). At 20% MVC, the median CoV of force [IQR] was 3.89% [1.65–8.75] for STN-DBS OFF, 1.92% [1.59–4.96] for 130-A, 2.98% [1.78–5.46] for 50 Hz, and 1.95% [1.42–3.02] for 130-B (Fig. 2d). Notably, at both contraction levels, the STN-DBS OFF condition showed the highest values and the greatest variability across participants, as indicated by the wider interquartile ranges. This suggests that in the absence of stimulation, force steadiness was both reduced and less consistent across individuals, whereas STN-DBS conditions (130 and 50 Hz) indicate a trend to lower and more stable CoV values. Friedman tests did not reveal significant overall differences between conditions at either 10% MVC (χ2(3) = 4.92, p = 0.18, Kendall’s W = 0.16) or 20% MVC (χ2(3) = 5.88, p = 0.12, Kendall’s W = 0.20). At 10% MVC, the median CoV [IQR] was 1.89% [1.48–2.42] in the UPDRS ≤ 25 group (n = 4) and 6.86% [3.78–13.51] in the UPDRS > 25 group (n = 6). A Mann–Whitney U test confirmed a significant group difference (U = 2, p = 0.038, effect size (Cliff’s δ = 0.83). At 20% MVC, the median CoV [IQR] was 1.54% [1.24–1.91] in UPDRS ≤ 25 versus 4.41% [2.66–9.49] in UPDRS > 25. The difference was significant (U = 1, p = 0.019, effect size Cliff’s δ = 0.92). These findings suggests that individuals with greater disease severity displayed markedly reduced force steadiness across all stimulation conditions. When restricting the analysis to the UPDRS > 25 subgroup, condition-specific comparisons provided further insights (Fig. 2e, f). At 10% MVC, median CoV [IQR] values were 13.51% [6.08–18.42] in STN-DBS OFF, 6.68% [2.77–17.71] in 130-A, 6.85% [5.25–10.16] in 50 Hz, and 5.70% [2.77–7.34] in 130-B. Similarly, at 20% MVC, median CoV [IQR] values were 6.91% [4.39–15.73] in STN-DBS OFF, 4.02% [1.84–5.46] in 130-A, 4.51% [2.83–8.06] in 50 Hz, and 2.84% [1.98–6.75] in 130-B. Friedman tests indicated significant overall effects of stimulation at both contraction levels (10% MVC: χ2(3) = 8.00, p = 0.046; 20% MVC: χ2(3) = 8.00, p = 0.046). Post hoc pairwise comparisons with Bonferroni correction revealed that force CoV was significantly lower in the 130-B condition compared to STN-DBS OFF (10% MVC: p = 0.044; 20% MVC: p = 0.044, Bonferroni corrected). By contrast, neither 130-A nor 50 Hz differed significantly from STN-DBS OFF. Taken together, these results suggest that although all stimulation settings tended to reduce force variability compared to the STN-DBS OFF condition, the last STN-DBS condition produced the most consistent improvements in patients with higher motor impairment. Figure 2c,d shows the force CoV for each participant across STN-DBS conditions to highlight individual variability. Discussion This explorative study investigated how different STN-DBS frequencies affect force steadiness in patients with Parkinson’s disease during submaximal contractions. By stratifying the participants according to disease severity (UPDRS-III > 25), all stimulation conditions tended to reduce CoV relative to STN-DBS OFF at both 10% and 20% of MVC and to lessen inter-individual variability, with a significant difference between 130-B and STN-DBS OFF. At a group level, a similar trend was observed with no statistical difference. Among the parameters tested, STN-DBS 130 Hz generally yielded the lowest CoV, suggesting better stabilization of force output than STN-DBS 50 Hz, which in some cases even worsened force steadiness relative to STN-DBS OFF. The overall trend was consistent across contraction levels, indicating that potential STN-DBS benefits extend across different motor demands. Subject-level data clarified how clinical severity and stimulation parameters shaped outcomes. Variability across conditions was most pronounced in participants with higher disease severity (UPDRS-III > 25), who also showed the largest STN-DBS -related reduction in force CoV. This suggests that suboptimal frequency selection can limit improvement or even impair motor stability. Subgroup analysis indicates that participants with higher UPDRS-III scores had significantly poorer baseline steadiness (STN-DBS OFF) than those with milder symptoms and indicated STN-DBS-related improvements. Within the UPDRS-III > 25 subgroups, the Friedman test indicated significant differences between STN-DBS conditions at both 10% and 20% of MVC force levels, and post hoc comparisons confirmed a significant reduction in force CoV during STN high-frequency stimulation (particularly the 130-B block) versus STN-DBS OFF after Bonferroni correction. Overall, our analysis suggests that STN-DBS benefits on hand force variability are more evident in participants with greater motor impairment, highlighting the importance of considering disease severity when evaluating fine motor performance. Participant-specific variability showed that, although 130 Hz STN-DBS generally produced the most consistent reductions in CoV, some participants presented reduced force CoV even at 50 Hz [5, 6, 13]. The observed changes in force steadiness may hypothetically reflect suppression of pathological beta-band (13–30 Hz) activity and reduced cortico-STN coherence under high-frequency stimulation, which have been associated with better motor performance; however, these study findings do not sufficiently back up such speculations and hence remain to be elaborated under a rigorous study protocol [16–19]. However, it cannot be excluded that the observed reduction in force CoV is partly influenced by tremor suppression rather than reflecting a pure improvement in motor steadiness. Oscillatory components in the low-frequency range may contribute to fluctuations in force output during isometric contractions and could be modulated by STN DBS. Therefore, the decrease in CoV observed under stimulation conditions may partly reflect a reduction in such oscillatory activity rather than solely improved neuromuscular control. As tremor-specific measures, such as UPDRS tremor sub-scores or spectral analysis of the force signal, were not included, the relative contribution of these mechanisms cannot be determined. Emerging adaptive STN-DBS approaches further highlight the need to customize stimulation parameters based on each person’s neurophysiological signature [20]. Previous experimental and clinical studies have shown that force steadiness is influenced by multiple factors, including neural control of force output, sensory feedback, and muscle properties, leading to intra- and interindividual variability in motor performance. These factors can be altered across the lifespan and in neurological disorders such as Parkinson’s disease, where impaired motor control (e.g., postural instability, disease progression, gait freezing) contributes to increased force variability. Greater coefficients of variation in force during low-force isometric contractions (5–20% MVC) have been reported in individuals with Parkinson’s disease compared to healthy controls. These findings suggest that alterations in motor control contribute to reduced force steadiness in neurological populations; however, the present study does not allow direct attribution of these effects to specific neural mechanisms, as no electrophysiological measurements were performed [21–26]. In the past, STN DBS studies have investigated the effects of frequency-dependent modulation on motor task performance of the upper limbs. Predominantly, these studies found a wide range of frequencies (from 80 to 130 Hz) capable of modulating motor control, in particular bradykinesia. Notably, Askari et al. determined differential effects on rigidity of the upper/lower limbs, suggesting downstream effects of STN DBS on motor networks and limb biomechanics, thus recommending to assess these effects under a holistic approach considering total electric energy dose (frequency, amplitude, intensity) [27–29]. Limitations The study protocol does not clearly separate frequency from overall stimulation energy as amplitude and pulse width were the same, the total electrical energy was higher at 130 Hz than at 50 Hz (total electrical energy dose; TEED), nor did we calculate TEED across the different STN DBS conditions. Each participant was measured under medication ON, defined as the best pharmacotherapeutic regime, which may differ and thus represents a relevant biasing factor. In clinical practice, STN-DBS optimization does not rely on frequency testing alone but on more systematic approaches such as contact selection and multiparameter adjustment. Without this broader framework, the conclusion that force steadiness could guide STN-DBS programming is not adequately supported by the data presented. This makes it difficult to state whether the changes in force steadiness are due to frequency or just differences in stimulation dose. Furthermore, all participants received the conditions in the same fixed order, which raises concerns about fatigue, habituation, or carryover effects. The fixed (non-randomized) order of STN-DBS patterns (130A–OFF–50 Hz–130B) represents a major limitation and confounds interpretation, making it difficult to isolate frequency-specific effects from dose effects. An additional limitation is that not all participants completed four ramps in every condition. Therefore, the analysis was standardized to two ramps per condition to ensure balanced comparisons across participants and conditions. Although this improved comparability, it reduced the amount of available data and may not fully capture within-condition variability. Furthermore, we solely tested participants under medication ON condition, thus lacking assessment of STN-DBS effects alone, which in turn increased variability (e.g., medication wearing off) between the different testing conditions along with a small sample size and hindered statistical power, thereby limiting generalizability. In addition, the stratification based on a UPDRS-III cutoff of 25 was exploratory and not based on predefined clinical thresholds, which may limit generalizability. It is noteworthy that any changes of STN-DBS frequencies may impact endogenous dopamine synthesis, thus potentially contributing to better performance of movement sequences. Notably, other targets than STN applied in patients with Parkinson’s disease such as the thalamic (VIM DBS) and the globus pallidus internus (GPi DBS) were not included in our study as comparative data regarding specific DBS targets would of have been of clinical research interest. Finally, the study protocol fails to inform on how quantification of hand force steadiness may add a value and facilitate STN DBS adjustment correlative with postural instability, disease progression, gait freezing, and the risk of falling. Conclusion The fact that differential effects were observed in patients with Parkinson’s disease with varying degrees of motor impairment is neither novel nor unexpected and in line with previously published data. The novelty of the current study appears to be a negative conclusion in that in the group of less severely affected patients with Parkinson’s disease no meaningful difference between high and low frequency stimulation parameters was detected with respect to force steadiness. STN-DBS likely acts primarily through affecting beta-band activity and modulates motor activity such as force steadiness. Responses to STN-DBS 50 Hz stimulation were highly variable across individuals, including cases where it improved, had no effect, or worsened force steadiness. Nevertheless, this may not limit the worthiness of this study, which is weakened by methodological issues, and suggests potential value; therefore, further clinical research is required to highlight the unresolved need for personalized STN-DBS programming. Thus, the authors advocate further randomized studies including a systematic integration and analysis of STN-DBS parameters (frequency, amplitude, pulse width, contact configuration) as integrating force steadiness measures into STN-DBS programming and evaluation might help tailor STN-DBS stimulation protocols to patient-specific clinical profiles, highlighting the importance of assessing STN-DBS effects on precision motor performance to improve functional outcomes. Acknowledgements We thank the participants of the study. Author Contributions All authors contributed to the study conception and design. Daniela Souza de Oliveira, Alessandro Del Vecchio, Thomas M. Kinfe and Amin Olamazadeh conducted the study. Material preparation, data collection and analysis were performed by Amin Olamazadeh, Steffen Brenner, Martin Regensburger, Daniela Souza de Oliveira, Alessandro Del Vecchio, Thomas M. Kinfe. All authors reviewed and edited the manuscript. All authors commented on previous version of the manuscript and approved the final version. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The Dr. Rolf Schwiete Stiftung and the University Heidelberg funded the Rapid Service Fee. Data Availability The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request. Declarations Conflict of Interest Thomas M. Kinfe, MD, PhD, works as a consultant for Abbott Inc. and has been paid for presentation and received conference travel support from Abbott Inc. and Thomas Kinfe is the founder and CEO of NAGUS Consulting. Amin Olamazadeh, Steffen Brenner, Daniela Souza de Oliveira, Martin Regensburger and Alessandro Del Vecchio have no conflicts of interest to declare. Ethical Approval The study protocol was approved by an independent internal local ethics committee (IRB No. 19-339-2-B), conducted in accordance with the principles of the latest revision of the Declaration of Helsinki. Written informed consent was obtained from all participants. Footnotes Amin Olamazadeh and Steffen Brenner contributed equally. References Associated Data Data Availability Statement The datasets generated during and/or analyzed during the current study are available from the corresponding authors on reasonable request.